Want to join the conversation?
$REGN 2Q15 Call: For Sarilumab, REGN reported positive data from three additional Phase 3 trials, including the SARIL-RA target study of Sarilumab in combination with non-biological disease modifying anti-rheumatic drugs or DMARD therapy. On track to submit BLA in the US by year-end and regulatory submission in Europe towards the end of next year.
Apple ($AAPL) reported decline in sales and profits from comparable quarter last year, attributing the decline to announcement of iPhone 7/7s. Sales and profit are being guided higher for next quarter. Apple is a solid company and will continue to dominate tech and consumer electronics segment for a while. Personally, looks like there is little downside in this investment.
Waiting with fingers crossed for $AAPL’s fourth quarter earnings.
Looking ahead to $AAPL earnings release later in the afternoon today? Gene Munster, analyst from Piper Jaffrey and the most respected authority for Apple, had this to say - "The second and slightly larger group of investors believe the tail of the iPhone 7 is irrelevant, and is betting that the iPhone 10th Anniversary will yield a jump in growth from flat to up ~15%."